Rationale: Hydrolysis of intracellular cholesterol ester (CE) is the key step in the reverse cholesterol transport in macrophage foam cells. We have recently shown that neutral cholesterol ester hydrolase (Nceh)1 and hormone-sensitive lipase (Lipe) are key regulators of this process in mouse macrophages. However, it remains unknown which enzyme is critical in human macrophages and atherosclerosis.
A therosclerotic cardiovascular diseases are the leading cause of mortality in industrialized countries, despite advances in the management of coronary risk factors. Heart attacks arise from the thrombotic occlusion of coronary arteries following the rupture of plaques. Lipid-rich plaques, which are characterized by a plethora of cholesterol ester (CE)-laden macrophage foam cells, are prone to rupture. 1 Esterification of cholesterol in macrophages is mediated by acyl-coenzyme A cholesterol acyltransferase 1 or sterol Oacyltransferase 1 (SOAT1). 2 Conflicting results have been reported as to the effects of genetic ablation of SOAT1 on atherosclerosis in mice. 3, 4 Furthermore, it has not been successful to demonstrate the efficacy of nonselective inhibitors of SOAT to clinically prevent the atherosclerosis in humans. 5, 6 On the other hand, the hydrolysis of intracellular CE is the initial step of reverse cholesterol transport. 7 As the hydrolysis of CE preceding reverse cholesterol transport takes place at neutral pH, the enzymes catalyzing it have been collectively called neutral CE hydrolases. Because this step is rate-limiting, particularly in macrophage foam cells, 8, 9 it is important to clarify the mechanisms that mediate the hydrolysis of CE in foam cells.
To date, 3 enzymes have been proposed to serve as neutral CE hydrolases in macrophages: hormone-sensitive lipase (LIPE) 10 ; cholesteryl ester hydrolase (CEH), 11 which is identical to human liver carboxylesterase 1 (CES1, hCE-1) 12 or macrophage serine esterase 1 (HMSE1), 13 also known as a human ortholog of triacylglycerol hydrolase 14 ; and neutral cholesterol ester hydrolase 1 (NCEH1), 15 which is also known as KIAA1363 or AADACL1 (arylacetamide deacetylaselike 1). 16 Lipe is expressed in mouse macrophages and its overexpression inhibits the accumulation of CE in THP-1 macrophages. 17, 18 However, mouse peritoneal macrophages (MPMs) of Lipe-deficient (Lipe Ϫ/Ϫ ) mice in a mixed genetic background still retain substantial neutral CE hydrolase activity, 19, 20 indicating the presence of additional neutral CE hydrolase(s). Ghosh reported CES1 as a promising candidate for a neutral CE hydrolase, 11 because its overexpression reduced CE contents in macrophage foam cells. 21, 22 Moreover, its macrophage-specific overexpression driven by the promoter of macrophage scavenger receptor-1 protected against diet-induced atherosclerosis in low-densitylipoprotein receptor-deficient mice. 23 However, the effects of loss-of function of CES1 on neutral CE hydrolase activity in macrophages have not been reported. Furthermore, a mouse ortholog of CES1, triacylglycerol hydrolase, was barely detectable in MPMs 15 and possessed negligible neutral CE hydrolase activity. 24 In contrast, Nceh1 is robustly expressed in MPMs as well as in atherosclerotic lesions. Its overexpression inhibits the accumulation of CE in THP-1 macrophages 15 and its knockdown or knockout significantly reduces neutral CE hydrolase activity of MPMs. 15, 25 We have also shown that Nceh1 is more responsible for the hydrolysis of CE in MPMs than in immortal cell line such as RAW 264.7. 15 Furthermore, ablation of Nceh1 accelerated atherosclerosis in mice. 25 Therefore, Nceh1 is more likely to be involved in the hydrolysis of CE in mouse macrophages including MPMs. However, NCEH1 in human macrophages has yet to be characterized. Furthermore, although Lipe contributes to neutral CE hydrolase activity in MPMs, 25 previous reports showed that expression of LIPE in human macrophages is extremely low. 15, 26, 27 Thus, there seems to be great differences in the hydrolysis of CE among macrophages from different species, and it is unknown which enzyme is the dominant neutral CE hydrolase in human macrophages. To solve this question and translate the findings to clinical application, we aimed to identify the enzyme responsible for CE hydrolysis in human macrophages and to determine its expression in human atherosclerotic lesions.
In the present study, we demonstrate for the first time that NCEH1 is expressed in macrophage foam cells in human atheromatous plaques and accounts for the majority of the neutral CE hydrolase activity of human monocyte-derived macrophages (HMMs). These findings should provide a novel paradigm for understanding the pathogenesis of human atherosclerosis as well as for developing new drugs for its treatment.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Western Blot Analyses
Western blotting analyses were performed essentially as described previously. 15 
Enzyme Assays
p-Nitrophenyl butyrate (PNPB)-hydrolyzing activity was determined as described previously. 11, 15 Neutral CE hydrolase activity was determined as described by Hajjar et al, 28 using a reaction mixture containing 6.14 mol/L cholesterol [1- 14 C]oleate (48.8 Ci/mol; 1 Ciϭ37 kBq).
Cholesterol Determination
Cellular cholesterol contents were determined by enzymatic fluorometric microassay. 4 
Cholesterol Formation

CE formation from [
14 C]oleate was measured. 29 
Samples for Immunohistochemistry
Tissue samples for immunohistochemistry analysis were obtained from autopsy cases. Arteriosclerotic lesions of the aorta were from 20 autopsy cases (Table) . After macroscopic inspection of the intimal surface, several tissue specimens were removed from the thoracic or abdominal aorta of these cases. Biopsy specimens were fixed in buffered formalin, embedded in paraffin wax, and serially sectioned onto 4-m-thick microscopic slides.
Immunohistochemistry
The method is described in detail in the Online Data Supplement.
Results
To determine which enzyme(s) is closely related to the neutral CE hydrolase activity at various stages in the differentiation of human macrophages, we compared the pattern of expression of NCEH1, CES1, and LIPE with that of neutral CE hydrolase activity during the differentiation of HMMs and 2 immortal lines: THP-1 and U937 ( Figure 1 ). Human NCEH1 protein was recognized as duplets with molecular mass of 40 and 45 kDa. HMMs showed a robust increase in neutral CE hydrolase activity during the differentiation from monocytes up to day 8 (14.9-fold) ( Figure 1A ). PNPB hydrolase activity in HMMs showed a similar, but less robust, increase (3.2-fold) ( Figure 1B ). The manner of its induction of the neutral CE hydrolase and PNPB hydrolase activity was similar to that of the expression of NCEH1, but not to the expression of CES1 ( Figure 1C) . We quantified the amounts of endogenous NCEH1 and CES1 in HMMs at day 8 of differentiation by estimating the density of band of NCEH1 or CES1 in HMMs, using GST-fused proteins, which were also used as antigens to produce anti-NCEH1 or CES1 antiserum, as standards (Online Figure I, A) . The molar ratio of NCEH1 to CES1 was calculated to be 10. However, NCEH1 was barely detectable, even at the differentiated stage, in either THP-1 cells or U937 cells, although the differentiation of these cells accompanied increases in neutral CE hydrolase activity. The level of NCEH1 was much lower in the liver or white adipose tissue (WAT) than in HMMs. LIPE was specifically expressed in WAT. LIPE protein was undetectable in HMMs and liver on Western blots using 3 different LIPE antibodies ( Figure 1C ). LIPE mRNA was detectable in HMMs and liver by quantitative real-time PCR, but the level was much lower compared that in WAT in accordance with the previous report (Online Figure I, B) . 27 In contrast to the relatively specific expression of these 2 enzymes, CES1 was expressed in the liver and WAT at a level comparable to that in HMMs, indicating the ubiquitous nature of its expression. The essential difference in expression profile between HMMs and immortal cell lines supports the idea that there are great differences in the hydrolysis of CE among macrophages from different species. We mainly focused on HMMs in subsequent experiments, because
HMMs are more relevant to the pathogenesis of human atherosclerosis.
We examined whether differences in cytokines used for differentiation of macrophages affect the expression of NCEH1, CES1, and LIPE and neutral CE hydrolase activity in HMMs. Treatment by macrophage colony-stimulating factor (M-CSF) or granulocyte/macrophage (GM)-CSF greatly increased the amounts of NCEH1 protein (M-CSF, 2.2-fold; GM-CSF, 3.4-fold). In parallel, it increased neutral CE hydrolase activity (M-CSF, 2.4-fold; GM-CSF, 3.5-fold) as reported previously (Online Figure II) . 30 GM-CSF slightly increased CES1 protein but LIPE was not affected.
To compare the ability of the overexpressed enzyme to remove CE from macrophage foam cells, we used an adenoviral vector to overexpress NCEH1, CES1, or LIPE in THP-1 cells that had been loaded with CE by incubation with acetylated low-density lipoprotein (acLDL) (Figure 2 ). Infection with increasingly higher doses of the adenoviral vectors resulted in the expression of the enzymes in a dose-dependent manner ( Figure 2A ). Neutral CE hydrolase activity in the whole cell lysate was increased robustly by Ad-LIPE (34-fold) and by Ad-NCEH1 to a lesser degree (3.2-fold). However, it was not affected by Ad-CES1, even at a multiplicity of infection (moi) of 300 ( Figure 2B ). PNPB hydrolase activity was increased by all 3 enzymes (Ad-NCEH1, 2.2-fold; Ad-CES1, 14-fold; Ad-LIPE, 4.6-fold), with the effect of Ad-CES1 most pronounced. The increased activity of neutral CE hydrolase, which was attained by infection with Ad-NCEH1 or Ad-LIPE, was associated with a decrease in the cellular CE content ( Figure 2D ), as well as in the rate of formation of CE from oleate ( Figure 2E ). However, overexpression of CES1 did not significantly reduce the cellular CE accumulation. The decreased CE formation was not accompanied by changes of level of SOAT1 protein ( Figure 2F) . Similarly, overexpression of NCEH1 or LIPE significantly decreased CE content in THP-1 cells, which had been loaded with oxidized LDL, aggregated LDL, or ␤-very-low-density lipoprotein (Online Figure IV) .
Cholesterol efflux was examined in THP-1 macrophages that overexpressed NCEH1, CES1, or LIPE (Online Figure  V) . Overexpression of NCEH1 and LIPE significantly promoted cholesterol efflux in the presence of high-density lipoprotein (HDL) (Online Figure V, Figure V, B) . Dibutyryl cAMP promoted cholesterol efflux in the cells overexpressing LIPE as described previously 18,31 but did not affect cholesterol efflux in the cells overexpressing NCEH1 or CES1, in accordance with our previous report (Online Figure V, D) . 32 Overexpression of NCEH1, CES1, or LIPE did not affect the expression of ABCG1 protein, whereas overexpression of NCEH1 or LIPE slightly increased the expression of ABCA1 protein (Online Figure V,  E) . These results indicate that human NCEH1 is primarily involved in CE hydrolysis and that its overexpression promotes cholesterol efflux without affecting SOAT1 activities probably by increasing the expression of ABCA1.
To determine whether LIPE or NCEH1 is involved in the hydrolysis of CE in HMMs, we used 76-0079, a LIPE inhibitor, 33 or AS115, a KIAA1363 inhibitor. 34 76-0079 was an inhibitor of both LIPE and CES1, and AS115 was an inhibitor of LIPE, NCEH1, and CES1 ( Figure 3A and 3B) . Although 76-0079 and AS115 are nonspecific inhibitors, we can estimate the contribution of NCEH1 by the difference between the effects of those inhibitors. First, we examined the effects of 76-0079 and AS115 on the neutral CE hydrolase ( Figure 3C and 3E) or PNPB hydrolase ( Figure 3D and 3F) activity in the whole cell lysate of HMMs, THP-1 macrophages, and U937 macrophages. 76-0079 did not significantly inhibit the neutral CE hydrolase activity of HMMs. In contrast, AS115 inhibited the neutral CE hydrolase activity by 85%. 76-0079 inhibited the PNPB hydrolase activity of HMMs, THP-1 cells, and U937 macrophages by 23%, 96%, and 80%, respectively. On the other hand, AS115 inhibited the PNPB hydrolase activities of these macrophages by 98%, 100% and 83%, respectively. Furthermore, whereas AS115 significantly decreased cholesterol efflux from HMMs that had been loaded with CE, 76-0079 did not ( Figure 3G ). These results support the notion that the neutral CE hydrolase activity of HMMs is primarily mediated by NCEH1 but not by CES1 or LIPE.
To determine whether NCEH1 or CES1 is involved in the hydrolysis of CE in HMMs, we used an RNA-silencing technique (Figure 4) . Infection with Ad-shNCEH1 reduced the amounts of NCEH1 protein as compared with Ad-shLacZ (by 41% at 250 mois and by 66% at 750 mois). In parallel, it decreased neutral CE hydrolase activity as compared with Ad-shLacZ (by 47% at 250 mois and by 50% at 750 mois). To the contrary, although infection with Ad-shCES1 reduced the amounts of CES1 protein as compared with Ad-shLacZ (by 60% at 250 mois and by 51% at 750 mois), it did not decrease the neutral CE hydrolase activity further from that attained with Ad-shLacZ. Infection with increasingly higher doses of Ad-shLacZ nonspecifically reduced the protein expression ( Figure 4A ) and neutral CE hydrolase activity ( Figure 4B ). To rule out the possibility that infection of Ad-shLacZ, Ad-shNCEH1, or Ad-shCES1 is cytotoxic, we performed MTT assay ( Figure 4C ). There was no significant difference in MTT activity among the cells infected with 3 viruses. Viability of cells infected 750 mois of adenovirus slightly decreased compared with no treatment cells, but the difference was not significant. Although there is a nonspecific effect of adenovirus infection, these results support that neutral CE hydrolase activity in HMMs is primarily mediated by NCEH1, not by CES1 or LIPE, in combination with the results of inhibition of human NCEH1 in HMMs by AS115 (Figure 3) .
Finally, we investigated the expression of NCEH1 in human aortas (Table) . We stained sections of aortas from 20 cases of autopsy whose clinical characteristics are summarized in Table. The lesions were morphologically classified into 3 types: diffuse intimal thickening, fatty streak lesions, and atheromatous plaques. 35 Atheromatous plaques were rich in cells positive for CD68, a pan-macrophage/dendritic cell marker, as well as NCEH1-positive cells compared with fatty streak lesions or diffuse intimal thickening. NCEH1-positive cells were absent in diffuse intimal thickening. Figure 5 shows representative sections from atheromatous plaques. This region contains acellular necrotic core ( Figure 5A ). The subintimal area between the intima and the necrotic core contained many CD68-positive cells ( Figure 5B) . A majority of the CD68-positve cells were also positive for NCEH1 ( Figure 5C and the Table) . The colocalizing characteristics of CD68 and NCEH1 were more obvious at a higher magnification ( Figure 5G and 5H) . In contrast, CES1 was weakly positive for some CD68-positive cells ( Figure 5D ). LIPE protein was barely detectable in HMMs in the same condition ( Figure 5E ). ACTA2 was strongly positive in most of the cells in the media and weakly positive for some of the cells in the intima (Figure 5F ). Furthermore, we show representative sections from fatty streak lesions (Online Figure VII, A through C). Although the expression of CD68 and NCEH1 in fatty streak lesions decrease compared with atherosclerotic plaque, many of the CD68-positve cells were also positive for NCEH1 (Online Figure VII, B and C) . CES1 was weakly expressed and LIPE was not expressed (data not shown). Thus, NCEH1 is the major enzyme that is specifically expressed in macrophages of human atherosclerotic lesions.
Discussion
Previously, we have reported that both Lipe and Nceh1 are involved in the hydrolysis of CE to a comparable degree in mice. 25 Circumstantial evidence, however, suggests that there are great differences in the hydrolysis of CE between human and mouse macrophages. 15, 26, 27 To understand the pathogenesis of atherosclerosis in humans, therefore, it is essential to determine the major enzyme that mediates the hydrolysis of CE hydrolysis in foam cell macrophages of human atherosclerotic lesions. In the present study, we show for the first time that NCEH1 is primarily involved in the hydrolysis of CE in human macrophages, thereby constituting the initial step toward reverse cholesterol transport in atherosclerotic lesions. We also show that contribution of CES1 and LIPE is trivial. Involvement of NCEH1 in atherosclerosis is further supported by its expression in situ in CD68-positive macrophages, which are abundant in human atheromatous plaques with cholesterol crystal in its necrotic core.
Recently, we have identified Nceh1 as a microsomal enzyme that mediates the hydrolysis of CE in mouse macrophages. 15, 32 In that report, we showed that the mRNA of a human ortholog of Nceh1 was markedly increased during the differentiation from human monocytes to mature macrophages. The present results confirm that the expression of NCEH1 protein was also markedly increased ( Figure 1C ). This level of induction was similar to the pattern of increase in neutral CE hydrolase activity ( Figure 1A ). Adenovirusmediated overexpression of human NCEH1 in CE-loaded THP-1 macrophages decreased the cellular CE content by stimulating cholesterol efflux along with the expression of ABCA1 ( Figure 2D ; Online Figure V) . On the other hand, inhibition of human NCEH1 by AS115, a KIAA1363 inhibitor, or RNA interference in HMMs significantly decreased neutral CE hydrolase activity ( Figure 3E and 4B) . Furthermore AS115 significantly decreased cholesterol efflux from HMMs which had been loaded with CE ( Figure 3G ). Thus, NCEH1 primarily regulates the hydrolysis of CE in HMMs.
Is NCEH1 the only enzyme with neutral CE hydrolase activity in human macrophages? This is a pressing question, because at least 2 other enzymes have been proposed to regulate neutral CE hydrolase activity in macrophages: LIPE and CES1. LIPE was the first enzyme proven to contribute to neutral CE hydrolase activity in macrophages. LIPE is indeed expressed in several macrophage cell lines including MPMs and preferentially catalyzes the hydrolysis of CE. 36, 37 Although some groups reported the expression of LIPE in human THP-1macrophages, 27 ,38 other groups doubted its role as a neutral CE hydrolase because of an extremely low level of expression as compared with that in adipose tissues. 31 The negligible expression of LIPE in HMMs was supported by the finding that efflux of cholesterol was not stimulated by cAMP, 31 which is known to stimulate lipolysis by activating LIPE in adipocytes. 39 Consistent with the claim of the latter groups, we failed to detect significant expression of LIPE in HMMs ( Figure 1C) . The negligible role of LIPE as a neutral CE hydrolase in human macrophages is also supported by the finding that 76-0079, a reportedly specific inhibitor of LIPE, did not significantly inhibit neutral CE hydrolase activity in HMMs ( Figure 3C ) and cholesterol efflux from HMMs which had been loaded with CE ( Figure 3G ). This can be extrapolated to other immortal cell lines of human macrophages: THP-1 and U937 macrophages. In mice, on the other hand, Lipe contributes to neutral CE hydrolase activity in MPMs. 25 Thus, there seems to be a species difference in terms of the relative role of LIPE in the hydrolysis of CE in macrophages.
The rediscovery of CES1 in human macrophages provided a second twist in the history of the investigation of neutral CE hydrolase in macrophages. CES1 was originally identified as a human carboxylesterase in both liver 12 and macrophages. 13 The use of different names for CES1 has complicated matters. Ghosh found neutral CE hydrolase activity in CES1. 11 Gosh and colleagues subsequently reported that overexpression of CES1 inhibits the accumulation of CE in macrophages. 21, 22 We tried to reproduce their findings in our model. So far, we have been unable to detect neutral CE hydrolase activity when overexpressed either in HEK293 cells (Online Figure  III) or in THP-1 macrophages ( Figure 2B ). Overexpression of CES1 did not reduce the amounts of CE in the cells even in the presence of the SOAT inhibitor (Online Figure V, B) . Thus, it is unlikely that CES1 stimulate reesterification of cholesterol directly or indirectly, thereby mitigating the effect of increased hydrolysis of CE on the cholesterol efflux. Although CES1 expression was recognized to a level comparable to that in the liver or WAT ( Figure 1C ), its silencing did not reduce the neutral CE hydrolase activity of HMMs ( Figure 4B ). Crow et al recently reported similar results: a recombinant CES1 protein did not possess neutral CE hydrolase activity. 40 Interestingly, they found that treatment of cholesterol-loaded THP-1 macrophages with ether paraoxon (a nonspecific CES inhibitor) or benzil (a specific CES inhibitor) caused enhanced retention of intracellular CE. This puzzling finding led them to speculate that the retention of CE is due in part to inhibition of enzymes other than CES1. Indeed, KIAA1363, an ortholog of NCEH1, is potently inhibited by many of organophosphates (OP) including paraoxon. 16, 41 There is a great difference in the ability to mobilize cholesterol between different types of macrophages. For example, THP-1 cells are known to be relatively ineffective at mobilizing cholesterol, primarily owing to slow hydrolysis of CE. 8, 42 In addition to the weak expression of LIPE, the absence of NCEH1 may explain the characteristics of THP-1 macrophages ( Figure 1C ). There are many other examples of differences in neutral CE hydrolase activity. 9, [43] [44] [45] It is tempting to speculate that these differences are attributable to the difference in the expression level of NCEH1. Furthermore, we examined the difference of the expression of NCEH1, CES1 and LIPE by M-CSF or GM-CSF treatment. NCEH1 protein and neutral CE hydrolase activity proportionally increased (Online Figure II) . In those M-CSF-or GM-CSFtreated HMMs, it is thought that NCEH1 greatly contributes to neutral CE hydrolase. It is further study to investigate difference of the contribution of NCEH1, CES1, and LIPE in macrophages stimulated by other cytokines or in different macrophages subclasses.
Finally, the expression of NCEH1 in CD68-positive macrophages in human atherosclerotic lesions in situ substantiates the role of NCEH1 in the development of atherosclerosis proposed above ( Figure 5 ). NCEH1 was expressed in CD68-positive macrophages, but not in other cells such as smooth muscle cells and endothelial cells. This pattern of expression is very similar to that of SOAT1. 35 The number of NCEH1-positive cells was generally larger in atheromatous plaques, which contain a necrotic center with a fibrous cap (Table) . Interestingly, the expression level of NCEH1 was not homogeneous in CD68-positive macrophages in those atherosclerotic lesions and spleen. Some CD68-positive macrophages weakly expressed NCEH1. Does this heterogeneity represent the presence of distinct subpopulations of macrophages? Does it just reflect the different stages of differentiation? These questions need to be answered to elucidate the precise pathogenesis of atherosclerosis.
In conclusion, we demonstrate for the first time that NCEH1 is quantitatively the most important neutral CE hydrolase in human macrophages and atherosclerosis. We also clearly show that the contribution of LIPE and CES1 is negligible compared with that of NCEH1, implying that we should be careful when findings in cholesterol metabolism of mice are extrapolated to those of humans. These findings indicate that NCEH is the only enzyme that requires attention when dealing with neutral CE hydrolase activity in human macrophages. Given its high levels in CD68-positive macrophages in initial fatty streaks, as well as in more advanced atheromatous plaques of human aortas, NCEH1 is a promising target for the treatment of atherosclerosis.
Novelty and Significance
What Is Known?
• Intracellular hydrolysis of cholesterol ester (CE) is the initial and rate-limiting step for removal of cholesterol from macrophage foam cells that predominate in fatty streak atherosclerotic lesions.
• Hormone-sensitive lipase (LIPE) and neutral cholesterol ester hydrolase (NCEH1) have comparable roles in CE hydrolysis in mouse macrophages, but the relative contribution of the hydrolytic enzymes in human macrophages is unknown.
What New Information Does This Article Contribute?
• NCEH1 is the principal enzyme that performs CE hydrolysis in human monocyte-derived macrophages (HMMs).
• The contributions of both cholesterol ester hydrolase (CES1) and LIPE to CE hydrolysis are trivial compared to NCEH1.
• NCEH1 is abundantly expressed in CD68-positive macrophages in cholesterol crystal-rich regions of human atherosclerotic lesions.
There is circumstantial evidence of differing contributions of NCEH1, LIPE, and CES1 to CE hydrolysis in macrophages of differing species. As we have reported previously, in mice, both LIPE and NCEH1 are involved in CE hydrolysis in macrophages. Although at least 3 enzymes are able to hydrolyze CE in nonlysosomal compartments in human macrophages, the relative contribution of these enzymes is controversial. The present study established the predominant role of NCEH1 compared with CES1 and LIPE in CE hydrolysis in human macrophages. Furthermore, we also demonstrated the expression of NCEH1 in macrophages in human atherosclerotic lesions. These findings facilitate the focus on NCEH1, a promising therapeutic target for promoting reverse cholesterol transport, and provide a novel paradigm for understanding the pathogenesis of human atherosclerosis.
